The Zhitong Finance App learned that Haitong International released a research report stating that maintaining the “superior to market” rating of Fangda Holdings (01521) was affected by the decline in global biomedical investment and financing growth, adjusted the company's 2024-2026 revenue to US$3,360, and 422 million, respectively; the adjusted net profit was US$0.34, 0.43, and US$52 million, with year-on-year growth rates of 40%, 28%, and 20%, respectively, cutting the target price from HK$3.4 to HK$1.89.
In North America, the company acquired Nuro-Technics in Toronto, Canada; integrated the business of BioTranexLaboratories, LLC and provided transporter research to enhance DMPK service capabilities; rapidly developed the pathology service team led by Dr. Stewart Jacobson; and strengthened the safety assessment operation facility in Chicago to enhance the two future services of ophthalmic toxicology and DART.
In China, the DMPK business has made progress in using human hepatocytes and high-throughput PAMPA screening to study BSEP and compound permeability; a new clinical sample production facility in Suzhou has enhanced clinical sample production capacity and helped achieve seamless drug research, development, and clinical trial supply, thereby speeding up the launch of drug clinical trials.